Precision BioSciences (DTIL) Competitors $4.96 +0.24 (+5.08%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends DTIL vs. ACRS, SCPH, SLN, CYBN, GNFT, LYEL, ACRV, ALEC, CHRS, and ADCTShould you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Aclaris Therapeutics (ACRS), scPharmaceuticals (SCPH), Silence Therapeutics (SLN), Cybin (CYBN), Genfit (GNFT), Lyell Immunopharma (LYEL), Acrivon Therapeutics (ACRV), Alector (ALEC), Coherus BioSciences (CHRS), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. Precision BioSciences vs. Aclaris Therapeutics scPharmaceuticals Silence Therapeutics Cybin Genfit Lyell Immunopharma Acrivon Therapeutics Alector Coherus BioSciences ADC Therapeutics Aclaris Therapeutics (NASDAQ:ACRS) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation. Do institutionals and insiders believe in ACRS or DTIL? 98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 6.4% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 4.0% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts rate ACRS or DTIL? Aclaris Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 328.02%. Precision BioSciences has a consensus price target of $37.67, suggesting a potential upside of 659.41%. Given Precision BioSciences' higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Aclaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, ACRS or DTIL? Precision BioSciences has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$27.08M6.78-$88.48M-$0.52-4.94Precision BioSciences$48.73M0.78-$61.32M$0.0682.68 Which has more volatility and risk, ACRS or DTIL? Aclaris Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Does the MarketBeat Community favor ACRS or DTIL? Aclaris Therapeutics received 292 more outperform votes than Precision BioSciences when rated by MarketBeat users. However, 68.15% of users gave Precision BioSciences an outperform vote while only 66.67% of users gave Aclaris Therapeutics an outperform vote. CompanyUnderperformOutperformAclaris TherapeuticsOutperform Votes38466.67% Underperform Votes19233.33% Precision BioSciencesOutperform Votes9268.15% Underperform Votes4331.85% Is ACRS or DTIL more profitable? Precision BioSciences has a net margin of 11.48% compared to Aclaris Therapeutics' net margin of -136.65%. Precision BioSciences' return on equity of -23.69% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-136.65% -40.26% -31.71% Precision BioSciences 11.48%-23.69%-6.98% Does the media prefer ACRS or DTIL? In the previous week, Aclaris Therapeutics had 2 more articles in the media than Precision BioSciences. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 0 mentions for Precision BioSciences. Aclaris Therapeutics' average media sentiment score of 0.58 beat Precision BioSciences' score of -0.67 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aclaris Therapeutics Positive Precision BioSciences Negative SummaryPrecision BioSciences beats Aclaris Therapeutics on 10 of the 19 factors compared between the two stocks. Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DTIL vs. The Competition Export to ExcelMetricPrecision BioSciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.04M$2.96B$5.21B$9.14BDividend YieldN/A1.91%5.13%4.02%P/E Ratio82.6845.5689.4217.36Price / Sales0.78275.871,240.0477.11Price / CashN/A192.9043.7535.97Price / Book1.093.965.314.79Net Income-$61.32M-$41.02M$122.54M$225.00M7 Day Performance-7.81%1.13%1.42%2.37%1 Month Performance5.08%-1.72%2.51%4.40%1 Year Performance-56.61%-2.23%25.29%20.10% Precision BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DTILPrecision BioSciences4.2848 of 5 stars$4.96+5.1%$37.67+659.4%-56.6%$38.05M$48.73M82.68200Short Interest ↑ACRSAclaris Therapeutics4.0912 of 5 stars$2.46-0.4%$11.00+347.2%+125.4%$175.72M$27.08M-4.7386Short Interest ↑SCPHscPharmaceuticals3.3354 of 5 stars$3.49+2.6%$15.00+329.8%-38.6%$174.64M$30.28M-1.8430SLNSilence Therapeutics2.1074 of 5 stars$5.83-2.7%$57.20+881.1%-72.2%$174.48M$16.25M-3.71100CYBNCybin2.9333 of 5 stars$8.68-2.4%$138.00+1,489.9%N/A$173.53MN/A-1.3050Positive NewsGNFTGenfit1.6411 of 5 stars$3.44-4.4%$13.00+277.9%+4.9%$171.99M$76.06M0.00120Short Interest ↑LYELLyell Immunopharma2.2103 of 5 stars$0.59-2.8%$1.00+70.3%-69.7%$171.59M$63,000.00-0.74270ACRVAcrivon Therapeutics1.7697 of 5 stars$5.46-0.2%$23.67+333.5%+32.9%$170.00MN/A-2.0258Short Interest ↑News CoveragePositive NewsALECAlector4.5046 of 5 stars$1.73-3.9%$3.75+116.8%-70.9%$169.42M$61.51M-1.02270Short Interest ↓Positive NewsCHRSCoherus BioSciences3.815 of 5 stars$1.46-0.7%$5.38+268.2%-43.0%$168.21M$304.34M-18.25330ADCTADC Therapeutics2.189 of 5 stars$1.72-8.8%$8.00+366.5%-0.3%$165.82M$70.72M-0.72310Negative News Related Companies and Tools Related Companies Aclaris Therapeutics Alternatives scPharmaceuticals Alternatives Silence Therapeutics Alternatives Cybin Alternatives Genfit Alternatives Lyell Immunopharma Alternatives Acrivon Therapeutics Alternatives Alector Alternatives Coherus BioSciences Alternatives ADC Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DTIL) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
